Skip to search formSkip to main contentSkip to account menu

RAD 001

Known as: 001, RAD, RAD001 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

everolimus

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
The mammalian target of rapamycin (mTOR) is regulated by oncogenic growth factor signals and plays a pivotal role in controlling… 
2011
2011
Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women…
1016 Background: TNBC is an aggressive disease and the only subtype with no specific targeted therapy. PI3K pathway activation… 
Highly Cited
2010
Highly Cited
2010
Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
8032 Background: Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or relapsed/refractory… 
2010
2010
Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST.
10038^ Background: RAD001 is an orally available inhibitor of mTOR. The PI3K (mTOR) pathway is frequently deregulated in human… 
2008
2008
A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously…
8051 Background: R is an oral inhibitor of the mammalian target of rapamycin (mTOR) in clinical development as an anticancer… 
Review
2008
Review
2008
A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma.
5104 Background: Both RAD001 and sorafenib have activity against advanced clear cell renal cell carcinoma (ccRCC). Inhibition of… 
2007
2007
Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial
7575 Background: Most non-small cell lung cancers (NSCLC) are primarily resistant to the EGFR tyrosine kinase inhibitor gefitinib… 
Highly Cited
2006
Highly Cited
2006
Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.
Rapamycin and its derivatives are promising anticancer agents, but the exact mechanisms by which these drugs induce cell cycle… 
2004
2004
Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy
Opinion statementGastrointestinal stromal tumors (GISTs) are rare tumors of the wall of the stomach and small bowel, and also… 
2000
2000
High-throughput analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system.
A semi-automated solid-phase extraction (SPE) liquid chromatography/mass spectrometry (LC/MS) procedure was validated for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)